What is required for prescribers, pharmacies, patients, and distributors to participate in the iPledge program?

The iPledge program is a medication-risk management system designed to prevent fetal exposure to teratogenic medications, specifically isotretinoin, and enforce its safe distribution. For prescribers, pharmacies, patients, and distributors to participate in the program, they must be registered.

Registration is essential as it ensures that all parties involved are aware of the requirements, understand the risks associated with the medication, and comply with the safety protocols established by the program. This includes the necessity to verify patient eligibility, educate patients about the risks, and monitor pregnancy status for individuals prescribed isotretinoin.

While other options like a special license, annual retraining, or background checks may be relevant in different contexts or programs, the core requirement for involvement in the iPledge program specifically centers around the registration process. This sets forth a framework for accountability and safety in prescribing and dispensing potentially harmful medications.